EUVIMEDEUVIMED entdecken
Open Access

Protective Non-neutralizing anti–N-terminal Domain mAb Maintains Fc-mediated Function against SARS-COV-2 Variants up to BA.2.86-JN.1 with Superfluous In Vivo Protection against JN.1 Due to Attenuated Virulence

Arman Izadi, Magdalena Godzwon, Anna Söderlund Strand, Tobias Schmidt, Susanna Kumlien Georén, Christian Drosten, Mats Ohlin iD, Pontus Nordenfelt iD

The Journal of Immunology · 2024

DOI: 10.4049/jimmunol.2300675 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, 2024. Verfasst von Arman Izadi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences Lund, Division of Infection Medicine, Faculty of Medicine, Lund University, Lund, Sweden. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2, Antibodies, Monoclonal, Antibodies, Viral. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Vetenskapsrådet (VR), Crafoordska Stiftelsen (The Crafoord Foundation).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Substantial evidence supports that Fc-mediated effector functions of anti-spike Abs contribute to anti–SARS-Cov-2 protection. We have previously shown that two non-neutralizing but opsonic mAbs targeting the receptor-binding domain and N-terminal domain (NTD), Ab81 and Ab94, respectively, are protective against lethal Wuhan SARS-CoV-2 infection in K18-hACE2 mice. In this article, we investigated whether these protective non-neutralizing Abs maintain Fc-mediated function and Ag binding against mutated SARS-CoV-2 variants. Ab81 and Ab94 retained their nanomolar affinity and Fc-mediated function toward Omicron and its subvariants, such as BA.2, BA.4, BA.5, XBB, XBB1.5, and BQ1.1. However, when encountering the more heavily mutated BA.2.86, Ab81 lost its function, whereas the 10 new mutations in the NTD did not affect Ab94. In vivo experiments with Ab94 in K18-hACE2 mice inoculated with a stringent dose of 100,000 PFU of the JN.1 variant revealed unexpected results. Surprisingly, this variant exhibited low disease manifestation in this animal model with no weight loss or death in the control group. Still, assessment of mice using a clinical scoring system showed better protection for Ab94-treated mice, indicating that Fc-mediated functions are still beneficial. Our work shows that a protective anti–receptor-binding domain non-neutralizing mAb lost reactivity when BA.2.86 emerged, whereas the anti-NTD mAb was still functional. Finally, this work adds new insight into the evolution of the SARS-CoV-2 virus by reporting that JN.1 is substantially less virulent in vivo than previous strains.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19SARS-CoV-2Antibodies, MonoclonalAntibodies, ViralSpike Glycoprotein, CoronavirusImmunoglobulin Fc FragmentsAnimalsMiceHumansVirulenceAntibodies, NeutralizingFemaleMice, Inbred BALB C

Substanzen

Antibodies, MonoclonalAntibodies, ViralSpike Glycoprotein, CoronavirusImmunoglobulin Fc FragmentsAntibodies, Neutralizingspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • Department of Clinical Sciences Lund, Division of Infection Medicine, Faculty of Medicine, Lund University, Lund, Sweden.
  • Department of Immunotechnology, Lund University, Lund, Sweden.
  • Department of Laboratory Medicine, Clinical Microbiology, Skåne University Hospital Lund, Lund University, Lund, Sweden.
  • Department of Clinical Sciences Lund, Division of Pediatrics, Faculty of Medicine, Lund University, Lund, Sweden.
  • Institute of Virology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Scantox A/S, Stockholm, Sweden.

ORCID-Profile: Mats Ohlin, Pontus Nordenfelt

Förderung

  • Vetenskapsrådet (VR)
  • Crafoordska Stiftelsen (The Crafoord Foundation)

Zitieren

APA

Izadi, A., Godzwon, M., Söderlund Strand, A., Schmidt, T., Kumlien Georén, S., Drosten, C., Ohlin, M., & Nordenfelt, P. (2024). Protective Non-neutralizing anti–N-terminal Domain mAb Maintains Fc-mediated Function against SARS-COV-2 Variants up to BA.2.86-JN.1 with Superfluous In Vivo Protection against JN.1 Due to Attenuated Virulence. The Journal of Immunology. https://doi.org/10.4049/jimmunol.2300675

Vancouver

Izadi A, Godzwon M, Söderlund Strand A, Schmidt T, Kumlien Georén S, Drosten C, et al. Protective Non-neutralizing anti–N-terminal Domain mAb Maintains Fc-mediated Function against SARS-COV-2 Variants up to BA.2.86-JN.1 with Superfluous In Vivo Protection against JN.1 Due to Attenuated Virulence. The Journal of Immunology. 2024. doi:10.4049/jimmunol.2300675

BibTeX
@article{Izadi2024,
  author = {Izadi, Arman and Godzwon, Magdalena and Söderlund Strand, Anna and Schmidt, Tobias and Kumlien Georén, Susanna and Drosten, Christian and Ohlin, Mats and Nordenfelt, Pontus},
  title = {Protective Non-neutralizing anti–N-terminal Domain mAb Maintains Fc-mediated Function against SARS-COV-2 Variants up to BA.2.86-JN.1 with Superfluous In Vivo Protection against JN.1 Due to Attenuated Virulence},
  journal = {The Journal of Immunology},
  year = {2024},
  doi = {10.4049/jimmunol.2300675}
}
Kostenlos starten →